


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Ilya Trakht  
 Serial No.: 09/767,578 Examiner: R.B. Schwadron  
 Filed: January 23, 2001 Group Art Unit: 1644  
 For: DEVELOPMENT OF HUMAN MONOCLONAL ANTIBODIES AND  
 USES THEREOF

1185 Avenue of the Americas  
 New York, New York 10036  
 December 9, 2004

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(c)(2) to supplement the Information Disclosure Statement filed August 23, 2001 in connection with the above-identified application.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit A**), and attached hereto as **Exhibits 1-8**, respectively:

1. U.S. Patent No. 4,714,681 A, issued December 22, 1987 to Reading et al. (**Exhibit 1**);
2. U.S. Patent No. 5,652,114 A, issued July 29, 1997 to Chu et al. (**Exhibit 2**);
3. European Patent Application No. 0 137 234 A2, published April 17, 1985 (**Exhibit 3**);
4. European Patent Application No. 0 695 760 A1, published

Applicant: Ilya Trakht  
Serial No.: 09/767,578  
Filed: January 23, 2001  
Page 2

February 7, 1996 (**Exhibit 4**);

5. European Patent Application No. 0 799 836 A1, published October 8, 1997 (**Exhibit 5**);
6. PCT International Publication No. WO 94/27638 A, published December 8, 1994 (**Exhibit 6**);
7. Carroll, W.L., Thielemans, K., Dilley, J. and Levy, R. (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89: 61-72 (**Exhibit 7**); and
8. Kearney, J.F., Radbruch, A., Liesegang, B. and Rajewsky K. (1979) new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123: 1548-1550 (**Exhibit 8**).

The Examiner is respectfully requested to make these references of record in the present application by initialing and returning a copy of the enclosed Form PTO-1449.

Applicant notes that the above-listed references were previously cited in a Supplementary European Search Report issued November 23, 2004 in connection with European Patent Application No. 99913925.6, a foreign counterpart of the subject application. References 7 and 8 listed above were also cited in a Supplementary Partial European Search Report issued September 8, 2004 in connection with the same European application. A copy of the November 23, 2004 Supplementary European Search Report is attached hereto as **Exhibit B**, and a copy of the September 8, 2004 Supplementary Partial European Search Report is attached hereto as **Exhibit C**.

Applicant notes also that the Kozbor et al. (1884) and Östberg et


Applicant: Ilya Trakht  
Serial No.: 09/767,578  
Filed: January 23, 2001  
Page 3

al. (1983) references cited in each of the above-identified European Search Reports (**Exhibits B and C**) are not listed in the present Supplemental Information Disclosure Statement because these references were previously made of record in the subject application, having been cited to the Examiner as references 34 and 37, respectively, in the Information Disclosure Statement filed August 23, 2001. Similarly, U.S. Patent Nos. 4,689,299 and 5,215,913 cited in the November 23, 2004 Supplementary European Search Report (**Exhibit B**) are not listed herein because they were previously disclosed as references 7 and 22, respectively, in the August 23, 2001 Information Disclosure Statement.


If a telephone conference would be of assistance in advancing the prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone them at the number provided below.

Pursuant to 37 C.F.R. §1.97(c)(2) and 1.17(p), a fee of one hundred and eighty dollars (\$180.00) is required for filing this Supplemental Information Disclosure Statement. Accordingly, a check in the amount of ONE HUNDRED EIGHTY DOLLARS (\$180.00) is enclosed. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

  
John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicant  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450

  
Alan J. Morrison  
Reg. No. 37,399

12/5/07  
Date

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
55099-B  
/JPW/AJM/AJDSerial No.  
09/767,578Applicant(s)  
Ilya TrakhtFiling Date  
January 23, 2001Group Art Unit  
1644**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Exh. No.	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate
	1	4	7	1	4	6	7	8	12/22/87	Reading et al.			
	2	5	6	5	2	1	1	4	07/29/97	Chu et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No
	3	0	1	3	7	2	3	4	04/17/85	EPO				
	4	0	6	9	5	7	6	0	02/07/96	EPO				
	5	0	7	9	9	8	3	6	10/08/97	EPO				
	6	9	4	2	7	6	3	8	12/08/94	PCT				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	7	Carroll, W.L., Thielemans, K., Dilley, J. and Levy, R. (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89: 61-72; and
	8	Kearney, J.F., Radbruch, A., Liesegang, B. and Rajewsky K. (1979) new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123: 1548-1550.

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Ilya Trakht  
U.S. Serial No.: 09/767,578  
Filed: January 23, 2001  
Exhibit A